Nxera Pharma Co Ltd is a science and technology-led biopharmaceutical company. Its activities are drug discovery, drug development and the commercialization of pharmaceutical products. The focus is to discover new medicines for unmet medical needs, including novel small molecules, peptides and therapeutic antibodies targeting G Protein Coupled Receptors (GPCRs).
1990
181
LTM Revenue $203M
LTM EBITDA $1.4M
$738M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Nxera Pharma has a last 12-month revenue of $203M and a last 12-month EBITDA of $1.4M.
In the most recent fiscal year, Nxera Pharma achieved revenue of $192M and an EBITDA of $0.7M.
Nxera Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Nxera Pharma valuation multiples based on analyst estimatesFY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
---|---|---|---|---|---|
Revenue | $84.8M | $192M | XXX | XXX | XXX |
Gross Profit | $97.3M | $64.2M | XXX | XXX | XXX |
Gross Margin | 115% | 34% | XXX | XXX | XXX |
EBITDA | -$37.9M | $0.7M | XXX | XXX | XXX |
EBITDA Margin | -45% | 0% | XXX | XXX | XXX |
Net Profit | $2.5M | -$47.8M | XXX | XXX | XXX |
Net Margin | 3% | -25% | XXX | XXX | XXX |
Net Debt | n/a | $134M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 25, 2025, Nxera Pharma's stock price is JPY 883 (or $6).
Nxera Pharma has current market cap of JPY 79.4B (or $528M), and EV of JPY 111B (or $738M).
See Nxera Pharma trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$738M | $528M | XXX | XXX | XXX | XXX | $-0.24 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 25, 2025, Nxera Pharma has market cap of $528M and EV of $738M.
Nxera Pharma's trades at 3.6x LTM EV/Revenue multiple, and 518.8x LTM EBITDA.
Analysts estimate Nxera Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Nxera Pharma and 10K+ public compsFY 2024 | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|
EV | $738M | XXX | XXX | XXX |
EV/Revenue | 3.9x | XXX | XXX | XXX |
EV/EBITDA | 1057.9x | XXX | XXX | XXX |
P/E | -16.4x | XXX | XXX | XXX |
P/E/Growth | n/a | XXX | XXX | XXX |
EV/FCF | -12.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpNxera Pharma's NTM/LTM revenue growth is 18%
Nxera Pharma's revenue per employee for the last fiscal year averaged $1.1M, while opex per employee averaged $1.0M for the same period.
Over next 12 months, Nxera Pharma's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Nxera Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Nxera Pharma and other 10K+ public compsFY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|---|
Revenue Growth | 126% | XXX | XXX | XXX | XXX |
EBITDA Margin | 0% | XXX | XXX | XXX | XXX |
EBITDA Growth | -102% | XXX | XXX | XXX | XXX |
Rule of 40 (SaaS-only) | 19% | XXX | XXX | XXX | XXX |
Revenue per Employee | $1.1M | XXX | XXX | XXX | XXX |
Opex per Employee | $1.0M | XXX | XXX | XXX | XXX |
S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
G&A Expenses to Revenue | 56% | XXX | XXX | XXX | XXX |
R&D Expenses to Revenue | 41% | XXX | XXX | XXX | XXX |
Opex to Revenue | 92% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Nxera Pharma acquired XXX companies to date.
Last acquisition by Nxera Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Nxera Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign UpWhen was Nxera Pharma founded? | Nxera Pharma was founded in 1990. |
Where is Nxera Pharma headquartered? | Nxera Pharma is headquartered in Japan. |
How many employees does Nxera Pharma have? | As of today, Nxera Pharma has 181 employees. |
Who is the CEO of Nxera Pharma? | Nxera Pharma's CEO is Mr. Christopher Cargill. |
Is Nxera Pharma publicy listed? | Yes, Nxera Pharma is a public company listed on TKS. |
What is the stock symbol of Nxera Pharma? | Nxera Pharma trades under 4565 ticker. |
When did Nxera Pharma go public? | Nxera Pharma went public in 2004. |
Who are competitors of Nxera Pharma? | Similar companies to Nxera Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
What is the current market cap of Nxera Pharma? | Nxera Pharma's current market cap is $528M |
What is the current revenue of Nxera Pharma? | Nxera Pharma's last 12-month revenue is $203M. |
What is the current EBITDA of Nxera Pharma? | Nxera Pharma's last 12-month EBITDA is $1.4M. |
What is the current EV/Revenue multiple of Nxera Pharma? | Current revenue multiple of Nxera Pharma is 3.6x. |
What is the current EV/EBITDA multiple of Nxera Pharma? | Current EBITDA multiple of Nxera Pharma is 518.8x. |
What is the current revenue growth of Nxera Pharma? | Nxera Pharma revenue growth between 2023 and 2024 was 126%. |
Is Nxera Pharma profitable? | Yes, Nxera Pharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.